subject area of
- A Bispecific Antifibrin-antiplatelet Urokinase Conjugate (BAAUC) Induces Enhanced Clot Lysis and Inhibits Platelet Aggregation Academic Article
- Activated platelets in the tumor microenvironment for targeting of antibody-drug conjugates to tumors and metastases Academic Article
- Antibody–drug conjugates in glioblastoma therapy: the right drugs to the right cells Academic Article
- Characterising the phenotypic evolution of circulating tumour cells during treatment Academic Article
- Characterization of ABBV-221, a Tumor-Selective EGFR-Targeting Antibody Drug Conjugate Academic Article
- Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma. Academic Article
- Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study Academic Article
- Induction of Specific T-Cell Responses, Opsonizing Antibodies, and Protection against Plasmodium chabaudi adami Infection in Mice Vaccinated with Genomic Expression Libraries Expressed in Targeted and Secretory DNA Vectors Academic Article
- Inhibition and Genetic Ablation of the B7/CD28 T-Cell Costimulation Axis Prevents Experimental Hypertension Academic Article
- Platelet-targeted dual pathway antithrombotic inhibits thrombosis with preserved hemostasis Academic Article
- Safety, pharmacokinetics, and antitumor response of depatuxizumab mafodotin as monotherapy or in combination with temozolomide in patients with glioblastoma Academic Article